| Product Unit Size | Cost | Quantity | Stock |
|---|
Baricitinib is a selective and reversible inhibitor of JAK1 and JAK2. In an HIV-associated neurocognitive disorder murine model, baricitinib was found to cross the blood-brain barrier and accumulate to adequate concentrations to reduce HIV-induced inflammation.
| Cas No. | 1187594-09-7 |
|---|---|
| Purity | ≥99% |
| Formula | C16H17N7O2S |
| Formula Wt. | 371.42 |
| Chemical Name | 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)- |
| IUPAC Name | 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)- |
| Synonym | INCB28050; LY3009104 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Gavegnano C, Haile WB, Hurwitz S, et al. Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro. J Neuroinflammation. 2019 Sep 27;16(1):182. PMID: 31561750.
Murakami K, Kobayashi Y, Uehara S, et al. A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro. PLoS One. 2017 Jul 14;12(7):e0181126. PMID: 28708884.
Ezzeldin E, Iqbal M, Asiri YA, et al. A hydrophilic interaction liquid chromatography-mass spectrometry quantitative method for determination of baricitinib in plasma, and its application in a pharmacokinetic study in rats. Molecules. 2020 Mar 31;25(7). pii: E1600. PMID: 32244454.
Fautrel B, Kirkham B, Pope JE, et al. Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM. J Clin Med. 2019 Sep 5;8(9): pii: E1394. PMID: 31492040.